When the proposed (quickly to be permitted) Fed. R. Civ. P. 16.1, regarding MDL observe was finalized final yr, we gave it one cheer in our “New Rule 16.1 – Better Than Nothing, But Not by a Lot” blogpost. We have been, and stay, involved that the supply regarding early vetting of MDL claimants will show insufficient to deal with the intense drawback created by big numbers of meritless claims. But we did level out that the part about exchanging details about the “factual foundation” of claims was totally different from the opposite gadgets on the rule’s matter record: it used “how and when,” versus “whether or not” or “if” – indicating that such early exchanges have been considered as obligatory (in some kind). This, we thought, gave the protection a gap for in search of severe early vetting of MDL claims.
That could already be taking place.
A latest order in Depo-Provera MDL is simply what defendants had hoped to see alongside these traces. Essentially, it’s a Lone Pine order, though that time period − which units off plaintiffs’ counsel – will not be used. The order requires each MDL grievance, whether or not pre-existing, transferred, or straight filed, to plead: (1) a “Requisite Physical Injury” from a specified record (no imprecise language disguising lack of precise harm); and (2) that such harm “resulted from and/or was exacerbated by . . . use of a Requisite Product,” once more from a specified record. The Depo Provera order solely imposes pleading necessities. It has no mandates, like some Lone Pine orders do, for professional submissions.
Nonetheless, the quick requirement of a selected assertion of illness, product identification, and causation is a giant chunk of the early vetting that MDLs so desperately want.
And there’s extra. Most MDL enforcement of plaintiffs failing to adjust to even fundamental discovery is an costly and drawn out course of requiring that the defendants spend effort and time to establish and pursue deficiencies whereas giving plaintiffs months and months to remedy these deficiencies. Not on this Depo Provera order. The defendants aren’t accountable for plaintiffs’ deficiencies. BrownGreer, already appointed to the place of MDL “Data Administrator,” is given enforcement authority:
BrownGreer will overview Complaints for deficiencies. . . . Specifically, if BrownGreer identifies a deficiency, it’ll notify the Plaintiff, who will then have a possibility to remedy by submitting an Amended Complaint to BrownGreer inside two enterprise days. . . . BrownGreer will then overview the Complaint once more for compliance. If BrownGreer finds the defect is cured, it’ll so notify the Plaintiff, who could then file the amended pleading on the person docket with out shifting for depart to amend. BrownGreer will inform the Court of any Plaintiff who has did not remedy the deficiency(cies) recognized by this course of. In these situations, the Court will first enter a docket annotation on the person docket directing the Plaintiff to deal with the remaining deficiencies by submitting an Amended Complaint inside seven days. If a person Plaintiff doesn’t well timed comply, the Court will difficulty a proper Order to Show Cause to deal with the deficiency or in any other case show why sanctions, as much as and together with dismissal, shouldn’t be imposed.
In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, 2025 WL 1618995, at *1 (N.D. Fla. May 12, 2025) (emphasis authentic).
Two days for preliminary deficiency discover, and 7 days for a judicial order to indicate trigger. That’s blazing quick. Moreover, poor complaints (a minimum of going ahead) can’t advance with out BrownGreer’s blessing. All of those features encourage plaintiffs to “put up or shut up” and to take action rapidly. That’s what early vetting is all about. Plaintiffs are purported to have Rule 11 compliant proof of product use, causation, and harm earlier than they file swimsuit. The formal course of that this order imposes is the primary one we’ve seen in a very long time that operates sufficiently rapidly to implement Rule 11 in a significant trend. The Depo-Provera order’s message is blunt − that plaintiffs whose pleadings fail minimal pleading requirements of the Federal Rules are going to be flagged, and failure to deal with these points promptly goes to end in immediate dismissal.
The identical decide getting into this order had the prior misfortune of presiding over a non-drug/system MDL, involving army earplugs, that quickly spiraled uncontrolled with an avalanche of questionable filings. That MDL, which reached some 270,000 plaintiffs (over 15% of all instances within the federal system), ultimately settled. Of course, it turned out that within the settlement course of, unhurt plaintiffs, product non-users, and duplicate claims abounded. Apparently, the courtroom is making a decided effort to require efficient early vetting this time round.
If the Depo-Provera order turns into a mannequin for MDL observe after Rule 16.1 goes into impact this December, then we’ll fortunately eat our phrases and admit that the whole course of could also be value it in spite of everything.